AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer
We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer. A panel of clini...
Uloženo v:
| Vydáno v: | The Journal of urology Ročník 198; číslo 4; s. 832 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.10.2017
|
| Témata: | |
| ISSN: | 1527-3792, 1527-3792 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer.
A panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus.
At this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer.
Although it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving. |
|---|---|
| AbstractList | We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer.
A panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus.
At this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer.
Although it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving. We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer.PURPOSEWe summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer, and provide practical recommendations for its use in the screening, diagnosis, staging and surveillance of prostate cancer.A panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus.MATERIALS AND METHODSA panel of clinicians with expertise in the diagnosis and management of prostate cancer evaluated the current published literature on the use and effectiveness of magnetic resonance imaging for this disease. When adequate studies were available for analysis, recommendations were made on the basis of data and when adequate studies were not available, recommendations were made on the basis of expert consensus.At this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer.RESULTSAt this time the data support the use of magnetic resonance imaging in patients with a previous negative biopsy and ongoing concerns about increased risk of prostate cancer. The data regarding its usefulness for initial biopsy suggest a possible role for magnetic resonance imaging in some circumstances. There is currently insufficient evidence to recommend magnetic resonance imaging for screening, staging or surveillance of prostate cancer.Although it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving.CONCLUSIONSAlthough it adds cost to the management of prostate cancer, magnetic resonance imaging offers superior anatomic detail, and the ability to evaluate cellular density based on water diffusion and blood flow based on contrast enhancement. Imaging targeted biopsy may increase the diagnosis of clinically significant cancers by identifying specific lesions not visible on conventional ultrasound. The clinical indications for the use of magnetic resonance imaging in the management of prostate cancer are rapidly evolving. |
| Author | Rukstalis, Daniel B Eggener, Scott Bjurlin, Marc A Fulgham, Pat F Carroll, Peter R Pinto, Peter A Turkbey, Ismail Baris Taneja, Samir Rubenstein, Jonathan N |
| Author_xml | – sequence: 1 givenname: Pat F surname: Fulgham fullname: Fulgham, Pat F email: pfulgham@airmail.net organization: Texas Health Presbyterian Hospital of Dallas, Dallas, Texas. Electronic address: pfulgham@airmail.net – sequence: 2 givenname: Daniel B surname: Rukstalis fullname: Rukstalis, Daniel B organization: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina – sequence: 3 givenname: Ismail Baris surname: Turkbey fullname: Turkbey, Ismail Baris organization: National Cancer Institute, National Institutes of Health, Bethesda, Maryland – sequence: 4 givenname: Jonathan N surname: Rubenstein fullname: Rubenstein, Jonathan N organization: Chesapeake Urology Associates, Baltimore, Maryland – sequence: 5 givenname: Samir surname: Taneja fullname: Taneja, Samir organization: NYU Langone Medical Center, New York, New York – sequence: 6 givenname: Peter R surname: Carroll fullname: Carroll, Peter R organization: University of California San Francisco, San Francisco, Calfornia – sequence: 7 givenname: Peter A surname: Pinto fullname: Pinto, Peter A organization: National Cancer Institute, National Institutes of Health, Bethesda, Maryland – sequence: 8 givenname: Marc A surname: Bjurlin fullname: Bjurlin, Marc A organization: NYU Langone Medical Center, New York, New York – sequence: 9 givenname: Scott surname: Eggener fullname: Eggener, Scott organization: The University of Chicago Medical Center, Chicago, Illinois |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28483574$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUMlOwzAQtVARXeAHOCAfOZBgO06cHKuyVWpFBfQcOckkuErsEjuHfgJ_TUKLxGmeZt4yM1M00kYDQteU-JTQ6H7n77rW-IxQ4RM-9M7QhIZMeIFI2OgfHqOptTtCKA8Fu0BjFvM4CAWfoO_5do43plb5Ab876aAB7bDR2H0C3lrApsTrrnZqL1vZgGtVjtey0uB68AbWaKlzwMtGVkpXWB2FD6qnGKvs3WD6O5G66IVaVqeEEm9aY4dEvBgs2kt0XsrawtWpztD26fFj8eKtXp-Xi_nKy0NGndfvLcsoTFhBeCYzQSXI_syQx1AkIiEsYwKikJSckYjGMYM8yvMg46LMaEE5m6Hbo---NV8dWJc2yuZQ11KD6WxK4ySKkyAKop56c6J2WQNFum9VI9tD-vc-9gMb6XU- |
| CitedBy_id | crossref_primary_10_1007_s00261_018_1771_1 crossref_primary_10_1007_s00330_020_07545_7 crossref_primary_10_1002_pros_24669 crossref_primary_10_4103_iju_iju_147_23 crossref_primary_10_1177_1756287221997186 crossref_primary_10_1016_j_eururo_2018_05_018 crossref_primary_10_2217_fon_2018_0287 crossref_primary_10_1016_j_juro_2018_07_034 crossref_primary_10_2147_CMAR_S283299 crossref_primary_10_1002_cam4_2149 crossref_primary_10_1056_NEJMoa1910038 crossref_primary_10_1097_MOU_0000000000000509 crossref_primary_10_1097_RCT_0000000000001514 crossref_primary_10_1016_j_juro_2018_03_027 crossref_primary_10_1007_s11255_025_04544_9 crossref_primary_10_1038_s41391_020_0223_5 crossref_primary_10_1038_s41391_024_00898_w crossref_primary_10_1016_j_juro_2018_04_078 crossref_primary_10_1177_15330338211019418 crossref_primary_10_1016_j_urolonc_2019_01_005 crossref_primary_10_1016_j_urology_2020_07_068 crossref_primary_10_1177_1756287219870074 crossref_primary_10_1088_1361_6560_aca954 crossref_primary_10_4103_iju_iju_115_24 crossref_primary_10_1001_jamanetworkopen_2021_32388 crossref_primary_10_1016_j_urology_2017_12_032 crossref_primary_10_1186_s12967_023_04424_9 crossref_primary_10_14366_usg_18003 crossref_primary_10_1007_s11934_019_0923_3 crossref_primary_10_1016_j_urolonc_2018_11_004 crossref_primary_10_1007_s00345_021_03743_0 crossref_primary_10_1016_j_euf_2019_03_016 crossref_primary_10_1007_s00261_018_1751_5 crossref_primary_10_1016_S1470_2045_18_30569_2 crossref_primary_10_1002_pros_24446 crossref_primary_10_3390_cancers14194824 crossref_primary_10_1002_pros_24843 crossref_primary_10_1038_s41598_019_43427_9 crossref_primary_10_1016_j_diii_2023_04_006 crossref_primary_10_1016_j_euf_2018_09_002 crossref_primary_10_1109_TMI_2022_3187873 crossref_primary_10_1016_j_juro_2017_07_012 crossref_primary_10_1148_radiol_2020190646 crossref_primary_10_1038_s41585_018_0060_7 crossref_primary_10_1016_j_urolonc_2020_11_016 crossref_primary_10_1007_s41972_018_0036_0 crossref_primary_10_1016_j_clinimag_2018_09_012 crossref_primary_10_1016_j_juro_2018_02_3126 crossref_primary_10_7759_cureus_73607 crossref_primary_10_1177_0284185120915617 crossref_primary_10_1111_bju_14759 crossref_primary_10_1002_uro2_18 crossref_primary_10_1097_CCO_0000000000000717 crossref_primary_10_1016_j_urolonc_2018_10_026 crossref_primary_10_1067_j_cpradiol_2024_04_002 crossref_primary_10_1056_NEJMoa2209454 crossref_primary_10_1007_s10334_022_01019_1 crossref_primary_10_1016_j_clgc_2022_01_013 crossref_primary_10_3348_kjr_2020_0837 crossref_primary_10_3390_cancers14215316 crossref_primary_10_3348_kjr_2020_0836 crossref_primary_10_1016_j_mednuc_2023_07_006 crossref_primary_10_1093_ajcp_aqz101 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.juro.2017.04.101 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3792 |
| ExternalDocumentID | 28483574 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Intramural NIH HHS grantid: Z01 BC011081 |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABPXF ABVCZ ABWVN ABXYN ABZZY ACGFS ACILI ACLDA ACOAL ACRPL ACVFH ACXJB ACZKN ADCNI ADGGA ADGHP ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AI. AIGII AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 ADKSD ADSXY |
| ID | FETCH-LOGICAL-c521t-835af6592d04bab71aea527548ed97902b27e650f42061882ec6cc3b47fb1d142 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 85 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000410478400074&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-3792 |
| IngestDate | Mon Sep 08 11:22:13 EDT 2025 Mon Jul 21 05:50:18 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | magnetic resonance imaging early detection of cancer image-guided biopsy prostatic neoplasms |
| Language | English |
| License | Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-835af6592d04bab71aea527548ed97902b27e650f42061882ec6cc3b47fb1d142 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7905434 |
| PMID | 28483574 |
| PQID | 1896893636 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1896893636 pubmed_primary_28483574 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-01 |
| PublicationDateYYYYMMDD | 2017-10-01 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 2017 |
| SSID | ssj0014572 |
| Score | 2.5323822 |
| SecondaryResourceType | review_article |
| Snippet | We summarize the available data about the clinical and economic effectiveness of magnetic resonance imaging in the diagnosis and management of prostate cancer,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 832 |
| SubjectTerms | Consensus Cost-Benefit Analysis Early Detection of Cancer - economics Early Detection of Cancer - methods Early Detection of Cancer - standards Feasibility Studies Humans Image-Guided Biopsy - economics Image-Guided Biopsy - methods Image-Guided Biopsy - standards Magnetic Resonance Imaging - economics Magnetic Resonance Imaging - methods Magnetic Resonance Imaging - standards Male Mass Screening - economics Mass Screening - methods Mass Screening - standards Neoplasm Staging - economics Neoplasm Staging - methods Neoplasm Staging - standards Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - economics Prostatic Neoplasms - pathology Societies, Medical - standards Ultrasonography, Interventional - methods Ultrasonography, Interventional - standards Urology - methods Urology - standards |
| Title | AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28483574 https://www.proquest.com/docview/1896893636 |
| Volume | 198 |
| WOSCitedRecordID | wos000410478400074&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_TG_iODRYpKmTXuSoQ49bOzgYLeRpqlMWDtX5__gf-17ScdOguCll5I0vLzk_fq-foTcMFYImWDplmUskAWTQYIhxFhHTOZxpuKocGQTqt9PRqN00Djc6iatcnknuos6rwz6yO94ksZgW-Mwvp99BMgahdHVhkJjnbRCgDKo1Wq0iiLIyJE3IXMrHKRUNEUzPr_rfTHH4j-usNUpZ_x3iOlMTXf3v4vcIzsNyKQdrxX7ZM2WB2Sr14TRD8l3Z9ihviMwdWgTXYS0KimgQTqsLa0K6ipzsTH4FDm3DO3ptxILHik6_LFLh6UvU0dxRCd-4KPP2pvUtzipe6PLnK4SbHDaAVaZwBfpA04xPyLD7tPrw3PQcDIEBqkPAgBsusBQbM5kpjPFtdUgXvjvsXmqUiYyoSygvkIKQAoA362JjQkzqYqM51yKY7JRVqU9JVQppJvJRWiklKATmYZ7FwCSSUWUcWHa5Hop5DHoPAYydGmrRT1eiblNTvxOjWe-OccYzC2sUcmzP4w-J9uoAD4374K0Cjjx9pJsmq_PST2_csoEz_6g9wMAFtKN |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AUA+Policy+Statement+on+the+Use+of+Multiparametric+Magnetic+Resonance+Imaging+in+the+Diagnosis%2C+Staging+and+Management+of+Prostate+Cancer&rft.jtitle=The+Journal+of+urology&rft.au=Fulgham%2C+Pat+F&rft.au=Rukstalis%2C+Daniel+B&rft.au=Turkbey%2C+Ismail+Baris&rft.au=Rubenstein%2C+Jonathan+N&rft.date=2017-10-01&rft.issn=1527-3792&rft.eissn=1527-3792&rft.volume=198&rft.issue=4&rft.spage=832&rft_id=info:doi/10.1016%2Fj.juro.2017.04.101&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon |